TBPH vs. ANNX, PLRX, AKRO, KNSA, SDGR, ARDX, TARO, EWTX, LGND, and MORF
Should you be buying Theravance Biopharma stock or one of its competitors? The main competitors of Theravance Biopharma include Annexon (ANNX), Pliant Therapeutics (PLRX), Akero Therapeutics (AKRO), Kiniksa Pharmaceuticals (KNSA), Schrödinger (SDGR), Ardelyx (ARDX), Taro Pharmaceutical Industries (TARO), Edgewise Therapeutics (EWTX), Ligand Pharmaceuticals (LGND), and Morphic (MORF). These companies are all part of the "pharmaceutical preparations" industry.
Theravance Biopharma (NASDAQ:TBPH) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation, community ranking and media sentiment.
In the previous week, Theravance Biopharma had 2 more articles in the media than Annexon. MarketBeat recorded 5 mentions for Theravance Biopharma and 3 mentions for Annexon. Annexon's average media sentiment score of 0.69 beat Theravance Biopharma's score of 0.46 indicating that Annexon is being referred to more favorably in the news media.
99.1% of Theravance Biopharma shares are held by institutional investors. 6.9% of Theravance Biopharma shares are held by insiders. Comparatively, 12.7% of Annexon shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Theravance Biopharma has higher revenue and earnings than Annexon. Theravance Biopharma is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks.
Theravance Biopharma has a beta of 0.36, meaning that its stock price is 64% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.
Theravance Biopharma presently has a consensus price target of $20.50, suggesting a potential upside of 143.76%. Annexon has a consensus price target of $15.33, suggesting a potential upside of 209.14%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Theravance Biopharma.
Theravance Biopharma received 292 more outperform votes than Annexon when rated by MarketBeat users. However, 73.33% of users gave Annexon an outperform vote while only 63.40% of users gave Theravance Biopharma an outperform vote.
Annexon has a net margin of 0.00% compared to Theravance Biopharma's net margin of -72.79%. Theravance Biopharma's return on equity of -18.97% beat Annexon's return on equity.
Summary
Theravance Biopharma and Annexon tied by winning 8 of the 16 factors compared between the two stocks.
Get Theravance Biopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Theravance Biopharma Competitors List
Related Companies and Tools
